338 related articles for article (PubMed ID: 3859928)
1. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
[No Abstract] [Full Text] [Related]
2. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Marit G; David B; Reiffers J; Broustet A
Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
[TBL] [Abstract][Full Text] [Related]
3. Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
Peters WG; Willemze R; Colly LP
Scand J Haematol Suppl; 1986; 44():7-16. PubMed ID: 3515513
[No Abstract] [Full Text] [Related]
4. Cytosine arabinoside in experimental combination therapy.
Edelstein M; Valeriote F
Semin Oncol; 1985 Jun; 12(2 Suppl 3):75-83. PubMed ID: 3892705
[No Abstract] [Full Text] [Related]
5. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
Keating MJ; Estey E; Plunkett W; Iacoboni S; Walters R; Kantarjian H; Andersson B; Beran M; McCredie KB; Freireich EJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):98-104. PubMed ID: 3859935
[No Abstract] [Full Text] [Related]
6. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside in the initial treatment of acute leukemia.
Barnett MJ; Waxman JH; Richards MA; Ganesan TS; Bragman KS; Rohatiner AZ; Lister TA
Semin Oncol; 1985 Jun; 12(2 Suppl 3):133-8. PubMed ID: 3859927
[No Abstract] [Full Text] [Related]
8. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Hines JD; Mazza JJ; Oken MM; Bennett JM; Adelstein DJ; Keller A; O'Connell MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):117-9. PubMed ID: 3839318
[No Abstract] [Full Text] [Related]
9. [Experiences with HD-Ara C treatment in leukemia patients].
Jehn U
Onkologie; 1985 Feb; 8(1):37-8. PubMed ID: 3885118
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
Tham RT; Peters WG; de Bruïne FT; Willemze R
AJR Am J Roentgenol; 1987 Jul; 149(1):23-7. PubMed ID: 3495987
[TBL] [Abstract][Full Text] [Related]
11. [A case of refractory acute lymphocytic leukemia responded to an intermediate-dose of cytosine arabinoside (ID Ara-C) therapy].
Hirota Y; Shibuya T; Ohhara N; Okamura S; Iwagiri R; Tada Y; Otsuka T; Nagano M; Tsuda Y; Niho Y
Rinsho Ketsueki; 1986 Jun; 27(6):941-6. PubMed ID: 3463812
[No Abstract] [Full Text] [Related]
12. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
13. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
[TBL] [Abstract][Full Text] [Related]
14. High-dose cytosine arabinoside in the treatment of childhood malignancies.
Lie SO; Slørdahl S
Semin Oncol; 1985 Jun; 12(2 Suppl 3):160-5. PubMed ID: 3859931
[No Abstract] [Full Text] [Related]
15. Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
Arlin ZA
J Clin Oncol; 1985 Jan; 3(1):128. PubMed ID: 3838101
[No Abstract] [Full Text] [Related]
16. Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C).
Steuber CP; Land VJ; Civin CI; Ragab AH; Krischer J; Vietti TJ
Invest New Drugs; 1987 Dec; 5(4):379-82. PubMed ID: 3481363
[TBL] [Abstract][Full Text] [Related]
17. High dose cytarabine: a review.
Bolwell BJ; Cassileth PA; Gale RP
Leukemia; 1988 May; 2(5):253-60. PubMed ID: 3287015
[TBL] [Abstract][Full Text] [Related]
18. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
[TBL] [Abstract][Full Text] [Related]
19. Experience with intermediate- and high-dose cytosine arabinoside in relapsed and refractory acute leukaemia.
Willemze R; Fibbe WE; Zwaan FE
Neth J Med; 1983; 26(8):215-9. PubMed ID: 6580554
[No Abstract] [Full Text] [Related]
20. High-dose cytosine arabinoside with amsacrine for treatment of acute lymphoblastic leukemia.
Arlin ZA
J Clin Oncol; 1986 Dec; 4(12):1868. PubMed ID: 3465878
[No Abstract] [Full Text] [Related]
[Next] [New Search]
